WJCD  Vol.4 No.7 , June 2014
New Developments in Anti-Anginal Therapy: Roles of Ivabradine, Allopurinol and of Agents Modifying Myocardial Metabolism
ABSTRACT
Over the last 20 years, it has emerged that, while surgical revascularisation of extensive ischaemic heart disease may have prognostic advantages, the main issues considered regarding individual management are usually those of symptomatic improvement only. The major impetus towards invasive intervention is therefore failure of prophylactic anti-anginal therapy. On the other hand, many patients, especially the elderly, now present the clinical problem of ongoing angina without residual invasive options. There is an ongoing need for more effective anti-anginal therapies. Of the currently available major classes of prophylactic anti-anginal agents, neither nitrates, β-blockers nor calcium antagonists generally produce marked improvements in exercise duration. Three areas of new therapeutic development in anti-anginal therapy are worthy of note. These involve the sinus node inhibitor ivabradine, high dose allopurinol (xanthine oxidase inhibitor) and a new class of “metabolic modulators” represented by perhexiline, trimetazidine and probably ranolazine. The current review addresses the therapeutic potential of these agents. Notably, all of these “new” drugs are potentially suitable for management of angina in the setting of impaired left ventricular systolic function, and they may also be utilized in patients with angina independent of the presence of coronary disease (for example in hypertrophic cardiomyopathy). The current evidence for efficacy and potential future development in this area are reviewed.

Cite this paper
Nguyen, T. , Chong, C. , Chan, W. and Horowitz, J. (2014) New Developments in Anti-Anginal Therapy: Roles of Ivabradine, Allopurinol and of Agents Modifying Myocardial Metabolism. World Journal of Cardiovascular Diseases, 4, 368-376. doi: 10.4236/wjcd.2014.47046.
References
[1]   Alderman, E.L., Bourassa, M.G., Cohen, L.S., Davis, K.B., Kaiser, G.G., Killip, T., Mock, M.B., Pettinger, M. and Robertson, T.L. (1990) Ten-Year Follow-Up of Survival and Myocardial Infarction in the Randomized Coronary Artery Surgery Study. Circulation, 82, 1629-1646.
http://dx.doi.org/10.1161/01.CIR.82.5.1629

[2]   Boden, W.E., O’Rourke, R.A., Teo, K.K., Hartigan, P.M., Maron, D.J., Kostuk, W.J., Knudtson, M., Dada, M., Casperson, P., Harris, C.L., Chaitman, B.R., Shaw, L., Gosselin, G., Nawaz, S., Title, L.M., Gau, G., Blaustein, A.S., Booth, D.C., Bates, E.R., Spertus, J.A., Berman, D.S., Mancini, G.B., Weintraub, W.S. and COURAGE Trial Research Group (2007) Optimal Medical Therapy with or without PCI for Stable Coronary Disease. The New England Journal of Medicine, 356, 1503-1516.
http://dx.doi.org/10.1056/NEJMoa070829

[3]   Munzel, T., Daiber, A. and Mulsch, A. (2005) Explaining the Phenomenon of Nitrate Tolerance. Circulation Research, 97, 618-628.
http://dx.doi.org/10.1161/01.RES.0000184694.03262.6d

[4]   Kleschyov, A.L., Oelze, M., Daiber, A., Huang, Y., Mollnau, H., Schulz, E., Sydow, K., Fichtlscherer, B., Mulsch, A. and Munzel, T. (2003) Does Nitric Oxide Mediate the Vasodilator Activity of Nitroglycerin? Circulation Research, 93, e104-112.
http://dx.doi.org/10.1161/01.RES.0000100067.62876.50

[5]   Walker, A., McMurray, J., Stewart, S., Berger, W., McMahon, A.D., Dargie, H., Fox, K., Hillis, S., Henderson, N.J. and Ford, I. (2006) Economic Evaluation of the Impact of Nicorandil in Angina (IONA) Trial. Heart, 92, 619-624.
http://dx.doi.org/10.1136/hrt.2003.026385

[6]   Fihn, S.D., Gardin, J.M., Abrams, J., Berra, K., Blankenship, J.C., Dallas, A.P., Douglas, P.S., Foody, J.M., Gerber, T.C., Hinderliter, A.L., King 3rd, S.B., Kligfield, P.D., Krumholz, H.M., Kwong, R.Y., Lim, M.J., Linderbaum, J.A., Mack, M.J., Munger, M.A., Prager, R.L., Sabik, J.F., Shaw, L.J., Sikkema, J.D., Smith Jr., C.R., Smith Jr., S.C., Spertus, J.A., Williams, S.V., F. American College of Cardiology, G. American Heart Association Task Force on Practice, P. American College of, S. American Association for Thoracic, A. Preventive Cardiovascular Nurses, A. Society for Cardiovascular, Interventions and S. Society of Thoracic (2012) 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions and Society of Thoracic Surgeons. Journal of the American College of Cardiology, 60, e44-e164.
http://dx.doi.org/10.1016/j.jacc.2012.07.013

[7]   Opie, L.H. and Horowitz, J.D. (2012) Nitrates and Newer Antianginals. In: Opie, L.H. and Gersh, B.J., Eds., Drugs for the Heart, Elsevier, Amsterdam, 38-64.

[8]   Fox, K., Ford, I., Steg, P.G., Tendera, M., Ferrari, R. and BEAUTIFUL Investigators (2008) Ivabradine for Patients with Stable Coronary Artery Disease and Left-Ventricular Systolic Dysfunction (BEAUTIFUL): A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet, 372, 807-816.
http://dx.doi.org/10.1016/S0140-6736(08)61170-8

[9]   George, J., Carr, E., Davies, J., Belch, J.J. and Struthers, A. (2006) High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid. Circulation, 114, 2508-2516.
http://dx.doi.org/10.1161/CIRCULATIONAHA.106.651117

[10]   Ekelund, U.E., Harrison, R.W., Shokek, O., Thakkar, R.N., Tunin, R.S., Senzaki, H., Kass, D.A., Marban, E. and Hare, J.M. (1999) Intravenous Allopurinol Decreases Myocardial Oxygen Consumption and Increases Mechanical Efficiency in Dogs with Pacing-Induced Heart Failure. Circulation Research, 85, 437-445.
http://dx.doi.org/10.1161/01.RES.85.5.437

[11]   Stull, L.B., Leppo, M.K., Szweda, L., Gao, W.D. and Marban, E. (2004) Chronic Treatment with Allopurinol Boosts Survival and Cardiac Contractility in Murine Postischemic Cardiomyopathy. Circulation Research, 95, 1005-1011.
http://dx.doi.org/10.1161/01.RES.0000148635.73331.c5

[12]   Noman, A., Ang, D.S., Ogston, S., Lang, C.C. and Struthers, A.D. (2010) Effect of High-Dose Allopurinol on Exercise in Patients with Chronic Stable Angina: A Randomised, Placebo Controlled Crossover Trial. Lancet, 375, 2161-2167.
http://dx.doi.org/10.1016/S0140-6736(10)60391-1

[13]   Rajendra, N.S., Ireland, S., George, J., Belch, J.J., Lang, C.C. and Struthers, A.D. (2011) Mechanistic Insights into the Therapeutic Use of High-Dose Allopurinol in Angina Pectoris. Journal of the American College of Cardiology, 58, 820-828.
http://dx.doi.org/10.1016/j.jacc.2010.12.052

[14]   George, J. and Struthers, A. (2009) The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) Trial: A Question of Dose. Journal of the American College of Cardiology, 53, 2405.
http://dx.doi.org/10.1016/j.jacc.2008.07.076

[15]   Kloner, R.A. and Nesto, R.W. (2008) Glucose-Insulin-Potassium for Acute Myocardial Infarction: Continuing Controversy over Cardioprotection. Circulation, 117, 2523-2533.
http://dx.doi.org/10.1161/CIRCULATIONAHA.107.697979

[16]   Howell, N.J., Ashrafian, H., Drury, N.E., Ranasinghe, A.M., Contractor, H., Isackson, H., Calvert, M., Williams, L.K., Freemantle, N., Quinn, D.W., Green, D., Frenneaux, M., Bonser, R.S., Mascaro, J.G., Graham, T.R., Rooney, S.J., Wilson, I.C. and Pagano, D. (2011) Glucose-Insulin-Potassium Reduces the Incidence of Low Cardiac Output Episodes after Aortic Valve Replacement for Aortic Stenosis in Patients with Left Ventricular Hypertrophy: Results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) Trial. Circulation, 123, 170-177.
http://dx.doi.org/10.1161/CIRCULATIONAHA.110.945170

[17]   Randle, P.J., Sugden, P.H., Kerbey, A.L., Radcliffe, P.M. and Hutson, N.J. (1978) Regulation of Pyruvate Oxidation and the Conservation of Glucose. Biochemical Society Symposium, 43, 47-67.

[18]   Horowitz, J.D., Chirkov, Y.Y., Kennedy, J.A. and Sverdlov, A.L. (2010) Modulation of Myocardial Metabolism: An Emerging Therapeutic Principle. Current Opinion in Cardiology, 25, 329-334.
http://dx.doi.org/10.1097/HCO.0b013e328339f191

[19]   Kennedy, J.A., Unger, S.A. and Horowitz, J.D. (1996) Inhibition of Carnitine Palmitoyltransferase-1 in Rat Heart and Liver by Perhexiline and Amiodarone. Biochemical Pharmacology, 52, 273-280.
http://dx.doi.org/10.1016/0006-2952(96)00204-3

[20]   Lyon, L.J., Nevins, M.A., Risch, S. and Henry, S. (1971) Perhexilene Maleate in Treatment of Angina Pectoris. Lancet, 297, 1272-1274.
http://dx.doi.org/10.1016/S0140-6736(71)91783-1

[21]   White, H.D. and Lowe, J.B. (1983) Antianginal Efficacy of Perhexiline Maleate in Patients Refractory to Beta-Adreno-receptor Blockade. International Journal of Cardiology, 3, 145-155.
http://dx.doi.org/10.1016/0167-5273(83)90030-X

[22]   Cole, P.L., Beamer, A.D., McGowan, N., Cantillon, C.O., Benfell, K., Kelly, R.A., Hartley, L.H., Smith, T.W. and Antman, E.M. (1990) Efficacy and Safety of Perhexiline Maleate in Refractory Angina. A Double-Blind Placebo-Controlled Clinical Trial of a Novel Antianginal Agent. Circulation, 81, 1260-1270.
http://dx.doi.org/10.1161/01.CIR.81.4.1260

[23]   Horowitz, J.D., Sia, S.T., Macdonald, P.S., Goble, A.J. and Louis, W.J. (1986) Perhexiline Maleate Treatment for Severe Angina Pectoris—Correlations with Pharmacokinetics. International Journal of Cardiology, 13, 219-229.
http://dx.doi.org/10.1016/0167-5273(86)90146-4

[24]   Kennedy, J.A. and Horowitz, J.D. (1998) Effect of Trimetazidine on Carnitine Palmitoyltransferase-1 in the Rat Heart. Cardiovascular Drugs and Therapy, 12, 359-363.
http://dx.doi.org/10.1023/A:1007768716934

[25]   Unger, S.A., Kennedy, J.A., McFadden-Lewis, K., Minerds, K., Murphy, G.A. and Horowitz, J.D. (2005) Dissociation between Metabolic and Efficiency Effects of Perhexiline in Normoxic Rat Myocardium. Journal of Cardiovascular Pharmacology, 46, 849-855.
http://dx.doi.org/10.1097/01.fjc.0000190488.77434.f1

[26]   Willoughby, S.R., Stewart, S., Chirkov, Y.Y., Kennedy, J.A., Holmes, A.S. and Horowitz, J.D. (2002) Beneficial Clinical Effects of Perhexiline in Patients with Stable Angina Pectoris and Acute Coronary Syndromes Are Associated with Potentiation of Platelet Responsiveness to Nitric Oxide. European Heart Journal, 23, 1946-1954.
http://dx.doi.org/10.1053/euhj.2002.3296

[27]   Gatto Jr., G.J., Ao, Z., Kearse, M.G., Zhou, M., Morales, C.R., Daniels, E., Bradley, B.T., Goserud, M.T., Goodman, K.B., Douglas, S.A., Harpel, M.R. and Johns, D.G. (2013) NADPH Oxidase-Dependent and -Independent Mechanisms of Reported Inhibitors of Reactive Oxygen Generation. Journal of Enzyme Inhibition and Medicinal Chemistry, 28, 95-104.
http://dx.doi.org/10.3109/14756366.2011.636360

[28]   Kennedy, J.A., Beck-Oldach, K., McFadden-Lewis, K., Murphy, G.A., Wong, Y.W., Zhang, Y. and Horowitz, J.D. (2006) Effect of the Anti-Anginal Agent, Perhexiline, on Neutrophil, Valvular and Vascular Superoxide Formation. European Journal of Pharmacology, 531, 13-19.
http://dx.doi.org/10.1016/j.ejphar.2005.11.058

[29]   Ngo, D.T., Drury, N.E., Pagano, D., Frenneaux, M.P. and Horowitz, J.D. (2011) How Does Perhexiline Modulate Myocardial Energetics and Ameliorate Redox Stress? Abstract. AHA 2011. Circulation, 124, Article ID: A14461.

[30]   Unger, S.A., Robinson, M.A. and Horowitz, J.D. (1997) Perhexiline Improves Symptomatic Status in Elderly Patients with Severe Aortic Stenosis. Australian and New Zealand Journal of Medicine, 27, 24-28.
http://dx.doi.org/10.1111/j.1445-5994.1997.tb00909.x

[31]   Lee, L., Campbell, R., Scheuermann-Freestone, M., Taylor, R., Gunaruwan, P., Williams, L., Ashrafian, H., Horowitz, J., Fraser, A.G., Clarke, K. and Frenneaux, M. (2005) Metabolic Modulation with Perhexiline in Chronic Heart Failure: A Randomized, Controlled Trial of Short-Term Use of a Novel Treatment. Circulation, 112, 3280-3288.
http://dx.doi.org/10.1161/CIRCULATIONAHA.105.551457

[32]   Abozguia, K., Elliott, P., McKenna, W., Phan, T.T., Nallur-Shivu, G., Ahmed, I., Maher, A.R., Kaur, K., Taylor, J., Henning, A., Ashrafian, H., Watkins, H. and Frenneaux, M. (2010) Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy. Circulation, 122, 1562-1569.
http://dx.doi.org/10.1161/CIRCULATIONAHA.109.934059

[33]   Brottier, L., Barat, J.L., Combe, C., Boussens, B., Bonnet, J. and Bricaud, H. (1990) Therapeutic Value of a Cardioprotective Agent in patients with Severe Ischaemic Cardiomyopathy. European Heart Journal, 11, 207-212.

[34]   Chazov, E.I., Lepakchin, V.K., Zharova, E.A., Fitilev, S.B., Levin, A.M., Rumiantzeva, E.G. and Fitileva, T.B. (2005) Trimetazidine in Angina Combination Therapy—The TACT Study: Trimetazidine versus Conventional Treatment in Patients with Stable Angina Pectoris in a Randomized, Placebo-Controlled, Multicenter Study. American Journal of Therapeutics, 12, 35-42.
http://dx.doi.org/10.1097/00045391-200501000-00006

[35]   Szwed, H., Sadowski, Z., Elikowski, W., Koronkiewicz, A., Mamcarz, A., Orszulak, W., Skibinska, E., Szymczak, K., Swiatek, J. and Winter, M. (2001) Combination Treatment in Stable Effort Angina Using Trimetazidine and Metoprolol: Results of a Randomized, Double-Blind, Multicentre Study (TRIMPOL II). European Heart Journal, 22, 2267-2274.
http://dx.doi.org/10.1053/euhj.2001.2896

[36]   Danchin, N., Marzilli, M., Parkhomenko, A. and Ribeiro, J.P. (2011) Efficacy Comparison of Trimetazidine with Therapeutic Alternatives in Stable Angina Pectoris: A Network Meta-Analysis. Cardiology, 120, 59-72.
http://dx.doi.org/10.1159/000332369

[37]   Chaitman, B.R., Pepine, C.J., Parker, J.O., Skopal, J., Chumakova, G., Kuch, J., Wang, W., Skettino, S.L., Wolff, A.A. for Combination Assessment of Ranolazine in Stable Angina Investigators (2004) Effects of Ranolazine with Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients with Severe Chronic Angina: A Randomized Controlled Trial. JAMA, 291, 309-316.
http://dx.doi.org/10.1001/jama.291.3.309

[38]   Zacharowski, K., Blackburn, B. and Thiemermann, C. (2001) Ranolazine, a Partial Fatty Acid Oxidation Inhibitor, Reduces Myocardial Infarct Size and Cardiac Troponin T Release in the Rat. European Journal of Pharmacology, 418, 105-110.
http://dx.doi.org/10.1016/S0014-2999(01)00920-7

[39]   Belardinelli, L., Shryock, J.C. and Fraser, H. (2006) Inhibition of the Late Sodium Current as a Potential Cardioprotective Principle: Effects of the Late Sodium Current Inhibitor Ranolazine. Heart, 92, iv6-iv14.
http://dx.doi.org/10.1136/hrt.2005.078790

[40]   Parker, J.O., Amies, M.H., Hawkinson, R.W., Heilman, J.M., Hougham, A.J., Vollmer, M.C., Wilson, R.R. and Minitran Efficacy Study Group (1995) Intermittent Transdermal Nitroglycerin Therapy in Angina Pectoris. Clinically Effective without Tolerance or Rebound. Circulation, 91, 1368-1374.
http://dx.doi.org/10.1161/01.CIR.91.5.1368

[41]   Chrysant, S.G., Glasser, S.P., Bittar, N., Shahidi, F.E., Danisa, K., Ibrahim, R., Watts, L.E., Garutti, R.J., Ferraresi, R. and Casareto, R. (1993) Efficacy and Safety of Extended-Release Isosorbide Mononitrate for Stable Effort Angina Pectoris. American Journal of Cardiology, 72, 1249-1256.
http://dx.doi.org/10.1016/0002-9149(93)90292-K

[42]   Jamal, S.M., Freedman, S.B., Thomson, A., Carter, G., Harris, P.J. and Kelly, D.T. (1987) Antianginal Efficacy of Carvedilol, a New Beta-Blocker with Vasodilating Action. Journal of Cardiovascular Pharmacology, 10, S141-S146.
http://dx.doi.org/10.1097/00005344-198710110-00026

[43]   Schnellbacher, K., Marsovszky, E. and Roskamm, H. (1986) Effect of Bisoprolol on Exercise Tolerance in Patients with Coronary Heart Disease: Placebo-Controlled Double-Blind Crossover Study. Journal of Cardiovascular Pharmacology, 8, S143-S147.
http://dx.doi.org/10.1097/00005344-198511001-00026

[44]   DiBianco, R., Singh, S., Singh, J.B., Katz, R.J., Bortz, R., Gottdiener, J.S., Spodick, D.H., Laddu, A.R. and Fletcher, R.D. (1980) Effects of Acebutolol on Chronic Stable Angina Pectoris. A Placebo-Controlled, Double-Blind, Randomized Crossover Study. Circulation, 62, 1179-1187.
http://dx.doi.org/10.1161/01.CIR.62.6.1179

[45]   Schwartz, J.B., Jackson, G., Kates, R.E. and Harrison, D.C. (1981) Long-Term Benefit of Cardioselective Beta Blockade with Once-Daily Atenolol Therapy in Angina Pectoris. American Heart Journal, 101, 380-385.
http://dx.doi.org/10.1016/0002-8703(81)90125-3

[46]   Hung, J., Lamb, I.H., Connolly, S.J., Jutzy, K.R., Goris, M.L. and Schroeder, J.S. (1983) The Effect of Diltiazem and Propranolol, Alone and in Combination, on Exercise Performance and Left Ventricular Function in Patients with Stable Effort Angina: A Double-Blind, Randomized, And Placebo-Controlled Study. Circulation, 68, 560-567.
http://dx.doi.org/10.1161/01.CIR.68.3.560

[47]   Pine, M.B., Citron, P.D., Bailly, D.J., Butman, S., Plasencia, G.O., Landa, D.W. and Wong, R.K. (1982) Verapamil versus Placebo in Relieving Stable Angina Pectoris. Circulation, 65, 17-22.
http://dx.doi.org/10.1161/01.CIR.65.1.17

[48]   Andreasen, F., Boye, E., Christoffersen, E., Dalsgaard, P., Henneberg, E., Kallenbach, A., Ladefoged, S., Lillquist, K., Mikkelsen, E., Norder, E., Olsen, J., Pedersen, J.K., Pedersen, V., Petersen, G.B., Schroll, J., Schultz, H. and Seidelin, J. (1975) Assessment of Verapamil in the Treatment of Angina Pectoris. European Journal of Cardiology, 2, 443-452.

[49]   Borer, J.S., Fox, K., Jaillon, P., Lerebours, G. and Ivabradine Investigators Group (2003) Antianginal and Antiischemic Effects of Ivabradine, an If Inhibitor, in Stable Angina: A Randomized, Double-Blind, Multicentered, Placebo-Controlled Trial. Circulation, 107, 817-823.
http://dx.doi.org/10.1161/01.CIR.0000048143.25023.87

[50]   Tardif, J.C., Ponikowski, P., Kahan, T. for the ASSOCIATE study Investigators (2009) Efficacy of the If Current Inhibitor Ivabradine in Patients with Chronic Stable Angina Receiving Beta-Blocker Therapy: A 4-Month, Randomized, Placebo-Controlled Trial. European Heart Journal, 30, 540-548.
http://dx.doi.org/10.1093/eurheartj/ehn571

 
 
Top